IRIS
FRANCHINI, SILVIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 158
EU - Europa 71
AS - Asia 14
Totale 243
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 158
IE - Irlanda 56
CN - Cina 14
IT - Italia 7
FI - Finlandia 5
DE - Germania 3
Totale 243
Salva come PNG Salva come JPEG
Città #
Dublin 56
Chandler 55
Ashburn 24
New York 16
Shanghai 12
Helsinki 5
Pavia 5
Lawrence 4
Medford 4
Princeton 4
Washington 3
Chicago 2
Los Angeles 2
Seattle 2
Wilmington 2
Woodbridge 2
Beijing 1
Boardman 1
Piscataway 1
Torino 1
Varese 1
Totale 203
Salva come PNG Salva come JPEG
Nome #
Identification of a Potent and Selective 5-HT1AReceptor Agonist with in Vitro and in Vivo Antinociceptive Activity 43
Admissions to emergency department appropriateness during covid-19 second wave in a large metropolitan hospital in northern italy 40
1,3-Dioxane as a scaffold for potent and selective 5-HT1AR agonist with in-vivo anxiolytic, anti-depressant and anti-nociceptive activity 38
Novel Dithiolane-Based Ligands Combining Sigma and NMDA Receptor Interactions as Potential Neuroprotective Agents 36
Effect of the rigidification of propranolol, a mixed β-adrenoceptor and 5-HT1AR antagonist 29
Investigation of the effect of different linker chemotypes on the inhibition of Histone Deacetylases (HDACs) 28
Scouting Sigma Receptor Ligands As New Tools For The Treatment Of Neurodegenerative Diseases And Cancer 27
Destabilizers of the thymidylate synthase homodimer accelerate its proteasomal degradation and inhibit cancer growth 9
Totale 250
Salva come PNG Salva come JPEG
Categoria #
all - tutte 1.290
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.290
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20216 0 0 0 1 1 0 0 2 2 0 0 0
2021/202216 0 0 4 0 0 0 0 1 2 0 1 8
2022/2023142 4 8 0 23 8 13 0 11 66 0 5 4
2023/202484 0 11 4 4 8 34 11 7 1 2 1 1
2024/20252 2 0 0 0 0 0 0 0 0 0 0 0
Totale 250